List of Excipients in Branded Drug CEFADROXIL

Generic Drugs Containing CEFADROXIL

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	cefadroxil	0093-3196	CROSCARMELLOSE SODIUM
Teva Pharmaceuticals USA Inc	cefadroxil	0093-3196	D&C YELLOW NO. 10 ALUMINUM LAKE
Teva Pharmaceuticals USA Inc	cefadroxil	0093-3196	FD&C BLUE NO. 1
Teva Pharmaceuticals USA Inc	cefadroxil	0093-3196	FD&C BLUE NO. 1 ALUMINUM LAKE
Teva Pharmaceuticals USA Inc	cefadroxil	0093-3196	FD&C BLUE NO. 2--ALUMINUM LAKE
Teva Pharmaceuticals USA Inc	cefadroxil	0093-3196	FD&C RED NO. 40

What are the Most Frequently-Used Excipients in CEFADROXIL?

# Of NDCs	Excipient
1	ALUMINUM OXIDE
24	CELLULOSE, MICROCRYSTALLINE
1	COLLOIDAL SILICON DIOXIDE
11	CROSCARMELLOSE SODIUM
21	CROSPOVIDONE
51	D&C RED NO. 28

Cefadroxil Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 25, 2026

Cefadroxil is an off-patent, orally administered first-generation cephalosporin with established use in capsules, tablets, and oral suspensions. Commercial opportunity is concentrated in low-cost generic supply, pediatric liquid formulations, taste-masked products, unit-dose packaging, and markets where reliable antibiotic availability is limited. The active ingredient does not have meaningful current regulatory exclusivity in the United States, and commercial differentiation depends primarily on product quality, palatability, stability, manufacturing efficiency, and distribution.

What is cefadroxil and how is it regulated?

Cefadroxil is a semisynthetic first-generation cephalosporin administered orally. It is commonly supplied as cefadroxil monohydrate and is indicated for susceptible bacterial infections, including selected infections of the urinary tract, skin, and respiratory tract.[1]

Attribute	Cefadroxil
Active ingredient	Cefadroxil monohydrate
Drug class	First-generation cephalosporin
Administration	Oral
Common dosage forms	Capsules, tablets, powder for oral suspension
Typical strengths	500 mg capsules and tablets; pediatric suspension strengths vary by market
Regulatory pathway	Generic drug approval through an abbreviated new drug application
Reference product history	Duricef and equivalent cefadroxil products
Current U.S. exclusivity	No meaningful active market exclusivity for the core drug
Biosimilar relevance	None; cefadroxil is a small-molecule drug
Primary commercial barriers	API quality, dissolution, suspension stability, taste, supply reliability, and pricing

The U.S. Food and Drug Administration classifies cefadroxil products as generic small-molecule drugs rather than biologics. Products must meet applicable requirements for identity, strength, quality, purity, stability, dissolution, labeling, and bioequivalence.[2]

What patents protect cefadroxil?

Cefadroxil’s original composition and product patents expired decades ago. The molecule is not commercially protected by a current composition-of-matter patent in the United States.

The Orange Book remains the principal source for identifying patents and regulatory exclusivities associated with approved U.S. drug products.[3] For an old generic active ingredient such as cefadroxil, the relevant commercial assessment is usually not whether the molecule remains patented, but whether a particular manufacturer has created a defensible formulation, process, device, or brand position.

Are there current cefadroxil formulation patents?

Potentially relevant intellectual-property positions could cover:

• Taste-masked cefadroxil granules or suspensions
• Extended-release oral dosage forms
• Improved powder-flow or granulation processes
• Stabilized aqueous suspensions
• Unit-dose reconstitution systems
• Combination products
• Packaging that improves moisture protection or dosing accuracy
• Manufacturing processes for cefadroxil monohydrate or a selected polymorphic form

These rights would need to be evaluated individually. A formulation patent does not restore broad exclusivity over cefadroxil. It can, however, create a narrower barrier against copying a specific dosage form or manufacturing method.

What is the Orange Book status of cefadroxil?

The practical Orange Book position is that cefadroxil is an established generic drug without a current core patent barrier comparable to protected branded medicines. Generic applicants generally compete through ANDA approval, not through a Paragraph IV strategy against a commercially important active patent.

The Orange Book should be checked at the time of filing because listed patents, discontinued products, and reference-product designations can change.[3]

When does cefadroxil lose exclusivity?

Cefadroxil already lost its original patent and market exclusivity. The commercial market is therefore mature and genericized.

There is no expected loss-of-exclusivity event comparable to a modern branded medicine. New entrants do not need to wait for a future core patent expiry, although they must obtain regulatory approval and satisfy current manufacturing and quality requirements.

Exclusivity category	Cefadroxil position
Original composition patent	Expired
Original product patent	Expired
New chemical entity exclusivity	Expired
Pediatric exclusivity	No current meaningful barrier
Orphan-drug exclusivity	Not applicable to the established product
Biologic exclusivity	Not applicable
Current market exclusivity	None of material commercial significance

What excipients are used in cefadroxil products?

The optimal excipient system depends on the dosage form. Cefadroxil products must balance chemical stability, dissolution, powder flow, suspension uniformity, taste, microbial protection, and patient adherence.

Capsule and tablet excipients

Immediate-release capsules and tablets generally use conventional excipients such as:

• Microcrystalline cellulose
• Lactose monohydrate
• Pregelatinized starch
• Maize starch
• Sodium starch glycolate
• Crospovidone
• Povidone
• Colloidal silicon dioxide
• Magnesium stearate
• Talc
• Film-coating polymers
• Titanium dioxide or permitted colorants

The formulation objective is straightforward: rapid disintegration, reproducible dissolution, adequate mechanical strength, and low manufacturing cost.

Cefadroxil is commonly administered without a modified-release delivery requirement. A conventional immediate-release platform therefore has a cost advantage over technically complex systems.

Oral suspension excipients

Suspensions create more meaningful formulation opportunities. Typical excipient functions include:

Function	Candidate excipient classes
Suspending agent	Xanthan gum, sodium carboxymethylcellulose, microcrystalline cellulose and carboxymethylcellulose combinations
Wetting agent	Polysorbates or other pharmaceutically acceptable surfactants
Sweetener	Sucrose, sucralose, saccharin sodium, sorbitol
Flavor	Fruit flavors, especially berry profiles
Buffer	Citrate, phosphate, or other suitable buffer systems
Preservative	Sodium benzoate, parabens, or other permitted preservatives
Bulking agent	Sucrose, mannitol, sorbitol
Anticaking or flow aid	Colloidal silicon dioxide
Colorant	Approved synthetic or natural colorants

The excipient choice must be compatible with cefadroxil’s stability profile and the intended reconstituted shelf life. The final product must maintain dose uniformity throughout the dosing interval, including after repeated shaking and storage under labeled conditions.

How should manufacturers approach cefadroxil taste masking?

Taste is one of the strongest commercial variables for pediatric cefadroxil products. Antibiotics often have strong bitterness or an unpleasant aftertaste, which can reduce adherence.

A practical strategy is to combine several controls:

1. Reduce direct contact between cefadroxil particles and taste receptors.
2. Use a high-efficiency sweetener system rather than relying only on sucrose.
3. Select a flavor that covers both bitterness and residual aftertaste.
4. Maintain acceptable viscosity without making the product difficult to pour or administer.
5. Evaluate taste after reconstitution and during the full in-use period.

Potential technologies include polymer coating, lipid coating, ion-exchange resin complexes, microencapsulation, and multiparticulate granules. These approaches may support a differentiated product, but they increase manufacturing complexity and may create new dissolution and bioequivalence risks.

For a standard generic, a conventional sweetened suspension may offer the best cost-to-market balance. For a pediatric specialty product, taste-masked granules or a low-sugar formulation may justify a higher price if clinical adherence or caregiver preference is improved.

What formulation opportunities exist for cefadroxil?

Pediatric low-sugar suspension

A low-sugar or sugar-free suspension could target pediatric patients, dental-risk concerns, and markets with demand for reduced-sucrose medicines. Polyols and high-intensity sweeteners can reduce sugar content, but they may introduce gastrointestinal tolerability issues or undesirable mouthfeel.

Ready-to-use liquid

A ready-to-use cefadroxil liquid would reduce caregiver preparation errors. Its commercial disadvantage is higher shipping weight and potentially shorter stability after manufacture. The product would need a robust preservative and stability package.

Extended-use reconstituted suspension

A formulation with a longer in-use shelf life could reduce pharmacy waste and improve supply in areas with inconsistent dispensing access. The key technical requirements are chemical stability, microbial control, sedimentation control, and dose uniformity.

Sprinkle or sachet formulation

A dry, taste-masked cefadroxil granule that can be mixed with a small volume of food or liquid could serve children who cannot swallow capsules. The product must control food compatibility, dose recovery, moisture sensitivity, and particle-size distribution.

Unit-dose packaging

Unit-dose sachets or premeasured bottles could reduce dispensing errors and support institutional, public-health, and tender markets. Packaging may offer stronger commercial differentiation than a conventional capsule, particularly where adherence and inventory control matter.

How strong is the cefadroxil patent estate?

The core patent estate is weak because the drug has been generic for many years. Patent strength is more likely to arise from a narrow formulation or manufacturing claim than from the active ingredient.

Patent category	Strategic value
Composition of matter	Very low; expired
Conventional capsule or tablet	Low unless a specific technical improvement is claimed
Pediatric suspension	Moderate if taste, stability, or dosing performance is distinctive
Modified release	Moderate, but clinical and bioequivalence hurdles are higher
Manufacturing process	Moderate if it provides measurable purity, yield, or stability advantages
Packaging and dosing system	Low to moderate; useful for product differentiation
Combination product	Potentially higher, but requires clinical and regulatory support

A formulation patent is strongest when it links a defined excipient ratio or process condition to a measurable technical result, such as improved stability, reduced bitterness, faster dissolution, or prolonged suspension uniformity. Broad claims covering routine excipient substitution are vulnerable to validity and obviousness challenges.

What FDA regulatory pathway applies to cefadroxil?

A conventional capsule, tablet, or suspension would generally use the ANDA pathway if a suitable reference-listed drug exists. The applicant must demonstrate pharmaceutical equivalence and bioequivalence and comply with current good manufacturing practice requirements.[2]

Regulatory development priorities include:

• API identity and assay
• Impurity and degradation-product control
• Particle-size control
• Content uniformity
• Dissolution testing
• Reconstitution performance
• Suspension redispersibility
• Microbial limits
• Preservative effectiveness
• In-use stability
• Container-closure integrity
• Labeling and dosing-device accuracy

A novel delivery system or materially different dosage form may require a more complex regulatory strategy. A 505(b)(2) application could be relevant where the product relies partly on existing safety information but introduces a meaningful formulation or delivery change.

What generic entry risks exist for cefadroxil?

The principal risk is not patent litigation. It is price erosion.

Cefadroxil has several characteristics that limit gross-margin expansion:

• Multiple established generic manufacturers
• Familiar API and dosage forms
• Limited need for specialized delivery technology
• Low switching costs for pharmacies and wholesalers
• Tender-driven purchasing in many markets
• Substitution by other oral cephalosporins or penicillin-class antibiotics where clinically appropriate

Manufacturers can reduce commodity exposure through pediatric formulations, reliable supply contracts, private-label partnerships, institutional packaging, and differentiated stability profiles.

What Paragraph IV challenges affect cefadroxil?

Paragraph IV litigation is unlikely to be commercially significant for the conventional cefadroxil market because the original patents have expired. A Paragraph IV filing would become relevant only if a newer formulation, method-of-use, or manufacturing patent were listed and commercially important.

Does cefadroxil face biosimilar risk?

No. Cefadroxil is a chemically synthesized small-molecule drug. It faces generic competition, not biosimilar competition. The relevant regulatory framework is the ANDA pathway rather than the abbreviated biologics license application pathway.

Which companies are challenging cefadroxil?

Cefadroxil competition is fragmented among generic manufacturers and regional pharmaceutical companies. The relevant competitors vary by country and dosage form. Common competitive categories include:

• Large U.S. generic suppliers
• Indian and European generic manufacturers
• Regional manufacturers serving public tenders
• Contract manufacturers supplying private-label products
• Branded-generic companies in emerging markets

Supplier selection should focus on FDA, EMA, or national regulatory history; cefadroxil API qualification; inspection record; capacity; shortage history; and ability to support pediatric suspension testing.

What licensing deals and commercial partnerships are relevant?

Cefadroxil is unlikely to attract major originator-style licensing transactions. Commercial partnerships are more likely to involve:

• API supply agreements
• Contract manufacturing
• Private-label distribution
• Regional commercialization rights
• Public-health procurement
• Pediatric formulation licensing
• Packaging and dosing-device partnerships

The most valuable licensable asset would generally be a differentiated formulation with evidence of improved taste, stability, dosing accuracy, or supply economics. A basic immediate-release capsule is more likely to be sourced through manufacturing or distribution contracts than through a high-value patent license.

What is the revenue exposure for cefadroxil products?

Revenue exposure is typically modest per product but can be durable when supported by institutional volume, pediatric demand, and reliable supply. The main revenue drivers are:

• Unit price after generic competition
• Contract and tender volume
• Product availability
• Pediatric suspension share
• Geographic access
• Manufacturing yield
• Packaging cost
• API procurement terms

A conventional capsule strategy prioritizes scale and low cost. A pediatric suspension strategy may support higher gross margins, but it requires more extensive stability, microbiology, taste, and packaging work.

How does cefadroxil compare with other oral antibiotics?

Factor	Cefadroxil	Cephalexin	Amoxicillin	Azithromycin
Drug class	First-generation cephalosporin	First-generation cephalosporin	Aminopenicillin	Macrolide
Core patent position	Expired	Expired	Expired	Expired
Typical administration	Often once or twice daily, depending on indication	Commonly multiple daily doses	Multiple daily doses depending on regimen	Often short-course dosing
Formulation opportunity	Suspension and taste masking	Suspension and taste masking	Suspension and combination products	Taste masking and suspension
Biosimilar risk	None	None	None	None
Main commercial lever	Supply, pediatric liquid, formulation quality	Broad generic availability	High volume and broad use	Dosing convenience

Cefadroxil can compete on dosing convenience against some older oral antibiotics, but prescribing depends on susceptibility, local resistance, infection site, clinical guidelines, and patient-specific factors. Marketing claims must remain within the approved label and applicable promotion rules.

What manufacturing and IP barriers matter most?

The most important manufacturing barriers are practical rather than patent-based:

• Consistent cefadroxil monohydrate quality
• Control of moisture and degradation
• Reliable particle-size distribution
• Reproducible granulation
• Fast and complete dissolution
• Stable suspension rheology
• Effective preservative system
• Accurate reconstitution instructions
• Robust bottle and closure design

For API producers, process patents may provide limited protection if they cover a non-obvious purification or crystallization method. For finished-dose manufacturers, process know-how can still create a cost advantage even when it is not patent-protected.

What generic launch scenarios are commercially realistic?

Low-cost capsule launch

This is the fastest and least differentiated route. It requires efficient sourcing and competitive pricing but offers limited protection against price compression.

Pediatric suspension launch

This route has higher development complexity and stronger opportunities for product differentiation through taste, reconstitution stability, sugar reduction, and dosing devices.

Institutional unit-dose launch

This approach targets hospitals, clinics, pharmacies, and public tenders. Packaging reliability and procurement economics matter more than consumer branding.

Regional private-label launch

A manufacturer can supply a branded-generic or private-label partner with capsules, tablets, or suspension. This reduces commercial overhead but shifts margin toward the distributor or brand owner.

Key Takeaways

• Cefadroxil is an established, off-patent small-molecule antibiotic with no biosimilar exposure.
• The core U.S. patent and exclusivity position is exhausted; conventional products face generic price competition.
• Excipient strategy matters most for oral suspensions, taste masking, sugar reduction, redispersibility, and in-use stability.
• Pediatric liquids, sprinkle granules, unit-dose packaging, and low-sugar products offer the strongest formulation opportunities.
• A conventional capsule or tablet is commercially viable mainly through low cost, reliable supply, and distribution scale.
• New patent value would likely come from a specific formulation, manufacturing process, or delivery system rather than cefadroxil itself.
• FDA development would generally proceed through an ANDA for conventional dosage forms, with a more complex pathway possible for novel delivery systems.
• The main commercial risks are price erosion, supplier competition, API quality failures, and inconsistent pediatric suspension performance.

FAQs

Is cefadroxil monohydrate different from cefadroxil?

Cefadroxil monohydrate is a hydrated solid form of cefadroxil used as the active pharmaceutical ingredient in many oral products. The labeled strength is expressed in terms of cefadroxil equivalent as required by the applicable product specification.

Can cefadroxil be formulated without sugar?

Yes. A sugar-free suspension can use polyols and high-intensity sweeteners, but the formulation must address bitterness, viscosity, gastrointestinal tolerability, preservative performance, and dose uniformity.

Does cefadroxil require a preservative in oral suspension?

A multidose aqueous suspension commonly requires microbial-control measures, which may include a preservative system. The need and selection depend on water activity, packaging, formulation pH, in-use period, and microbiological testing.

Can a cefadroxil suspension be protected by a new patent?

Yes, if the formulation contains a novel and non-obvious technical feature that produces a measurable benefit, such as improved taste masking, stability, dissolution, or suspension uniformity. Routine excipient substitution is less likely to support durable patent protection.

Is cefadroxil suitable for a 505(b)(2) product?

A conventional cefadroxil capsule, tablet, or suspension would generally be more naturally developed through the ANDA pathway. A 505(b)(2) strategy could be considered for a materially different delivery system or formulation that relies partly on existing safety information.

References

1. U.S. National Library of Medicine. (n.d.). Cefadroxil: Drug label information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2014). Abbreviated new drug application process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book